Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec.

The milestone was for the transition of a respiratory programme into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the sixteenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of this programme into pre-clinical development. The alliance continues to achieve significant scientific and commercial success, reflecting the truly collaborative efforts of teams from Evotec and Boehringer Ingelheim.”